Pfizer has reported the death of a patient in the Phase II DAYLIGHT study of experimental gene therapy, fordadistrogene ...

Sanofi's CSO has left the company amid a global R&D restructuring. Pfizer tags longtime Citi analyst for C-suite-level ...

A woman has come forward claiming to be a Pfizer whistleblower with a helluva story to tell about the pharmaceutical giant.

Pfizer recently announced plans to shut down its Boulder operations, but the life sciences industry is seeing the biopharmaceutical giant's departure as an opportunity.

Pfizer Inc. has agreed to settle more than 10,000 cases accusing ... tests showing the likely carcinogen NDMA in the drug and ...

An analyst from Morgan Stanley persists with their Equal-Weight rating on Pfizer, maintaining a target price of $29.

Pfizer has paused enrollment in a Phase III trial assessing its Duchenne muscular dystrophy (DMD) gene therapy candidate ...

Pfizer Inc., New York and Kano State Government held their routine annual meeting on Tuesday to highlight the work of the International Independent Research Trust and its efforts in establishing a ...

Pfizer stock rose as markets opened Wednesday following an earnings report that included sales growth among Pfizer's ...

Andrew Baum has worked at Citi since 2011 following a 14-year stint at Morgan Stanley, where he covered European ...

Citi analyst Andrew Baum, after covering Pfizer for more than a decade, will join the Big Pharma company as chief strategy and innovation officer. In the role, he'll oversee the drugmaker's portfolio ...

Pfizer's stock is undervalued compared to its peers, offering a higher-than-average dividend yield. Find out if now is a good ...